Also Known As: Tenofovir/emtricitabine, Truvada
Tenofovir/emtricitabine, trademark Truvada by Gilead Sciences, is a fixed-dose combination of twoantiretroviral drugs used for the treatment of HIV. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine.
The drug has been examined for use as a pre-exposure prophylaxis against HIV infection. A Cochrane review found that both tenofovir alone, as well as the tenofovir/emtricitabine combination, significantly decreased the risk of contracting HIV. The Food and Drug Administration approved it for prophylactic use on July 16, 2012. It is estimated that daily intake of Truvada achieves a 99% of risk reduction of contracting HIV in high risk individuals.